Phase II study of narrow band ultraviolet therapy for treatment-refractory skin graft versus host disease complicated with allogeneic hematopoietic stem cell transplantation - Phase II study of NBUV for skin GVHD

KURODA JUNYA0 个研究点目标入组 40 人开始时间: 2018年10月31日最近更新: 2023年10月17日

试验速览

暂无简介。

•1. Patient who receives treatment between the date of jRCT release and March 31st 2026
•2. Post-allogeneic hematopoietic stem cell transplantation patient with treatment-refractory acute skin GVHD which is defined by the disease status which is not improved by 5 days treatment with corticosteroid.
•3. Patient with acute skin GVHD which is histologically diagnosed.
•4. Grade I to II acute GVHD
•5. Patient who is able to have written informed consent for the study enrollment
•6. Age between 16 to 70 at the informed consent
•7. No restriction for gender
•8. Both outpatient and inpatient are eligible
•9. Performance status 0-2 defined by Eastern Cooperative Oncology Group criteria

•1. Pregnant female patient
•2. Poor control diabetes mellitus
•3. Any severe infection
•4. Treatment-difficult skin disease other than GVHD
•5. Patients with Grade 3 or worse GVHD
•6. Patients with photodermatosis, or those take drugs which may cause photodermatosis
•7. Patients whom an attending physician consider not appropriate for study enrollment

发起方

KURODA JUNYA